Researchers hope to do so if the infection increases the threat of headaches such as prematurity, fetal expansion delay, stillbirth, newborn death and birth defects.
Photo on its own. Source: iStock.
Washington, September 2
A leading clinical organization in the U.S.But it’s not the first time It has presented a study to track prevalence and have an effect on COVID-19 infection in approximately 16,000 pregnant women in seven countries, adding India.
The test will focus on pregnant women and 12 months after delivery to compare maternal, fetal and neonatal outcomes of inflamed participants with the virus with those of pregnant women who have not become inflamed, the National Institute of Health (NIH) said, leading the test launch Tuesday.
India, Bangladesh, Pakistan, Kenya, Zambia, Democratic Republic of the Congo and Guatemala, he said.
It will be conducted through the Global Network for Research on Women’s and Children’s Health, an organization of clinical sites funded through the NIH National Institute of Child Health and Human Development (NICHD), Eunice Kennedy Shriver.
During childbirth, women enrolled in the test will get an antibody check to check if they have been exposed to SARS-CoV-2, the virus that causes COVID-19, niH said in a statement.
Researchers hope to know if the infection increases the threat of headaches such as prematurity, fetal expansion delay, stillbirth, newborn death and birth defects.
They also hope to assess participants’ wisdom and attitudes toward COVID-19 pregnancy, adding safety, protective practices and prenatal care.
Women on the test will also be asked to participate in follow-up research to determine whether maternal SARS-CoV-2 infection influences the baby’s outcomes, such as cerebral palsy, developmental delays, and auditory and visual abnormalities, the NIH said.
The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).